aa 214 abiotic stress blocker PCR Glycyrrhiza hormonal treatment kit torrent KRAS mutations marker proteins medicinal plant mlcard modified oligonucleotides mutation detection
The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer
The clustered recurrently interspaced brief palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system was initially found in prokaryotes and features as a part of the adaptive immune system. The experimental analysis of many students, in addition to scientific and technological developments, has allowed prokaryote-derived CRISPR/Cas genome-editing programs to rework our potential to govern, detect, picture, and annotate particular DNA and RNA sequences within the dwelling cells of numerous species.
Via trendy genetic engineering enhancing expertise and high-throughput gene sequencing, we will edit and splice covalently closed round DNA to silence it, and proper the mutation and deletion of liver most cancers genes to attain exact in situ restore of faulty genes and prohibit viral an infection or replication. Such manipulations don’t destroy the construction of your complete genome and facilitate the remedy of illnesses.
On this assessment, we mentioned the likelihood that CRISPR/Cas may very well be used as a therapy for sufferers with liver most cancers attributable to hepatitis B virus an infection, and reviewed the challenges incurred by this efficient gene-editing expertise.
Utility of the CRISPR/Cas9-based gene enhancing approach in fundamental analysis, analysis, and remedy of most cancers
The 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna for the event of the Clustered recurrently interspaced brief palindromic repeats/CRISPR-associated nuclease9 (CRISPR/Cas9) gene enhancing expertise that offered new instruments for exact gene enhancing.
It’s attainable to focus on any genomic locus just about utilizing solely a fancy nuclease protein with brief RNA as a site-specific endonuclease. Since most cancers is attributable to genomic adjustments in tumor cells, CRISPR/Cas9 can be utilized within the area of most cancers analysis to edit genomes for exploration of the mechanisms of tumorigenesis and growth.
In recent times, the CRISPR/Cas9 system has been more and more utilized in most cancers analysis and therapy and memorable outcomes have been achieved. On this assessment, we launched the mechanism and growth of the CRISPR/Cas9-based gene enhancing system.
Moreover, we summarized present purposes of this method for fundamental analysis, analysis and remedy of most cancers. Furthermore, the potential purposes of CRISPR/Cas9 in new rising hotspots of oncology analysis had been mentioned, and the challenges and future instructions had been highlighted.
Utility of CRISPR-Cas9 based mostly gene enhancing to review the pathogenesis of colon and liver most cancers utilizing organoids
Two breakthrough strategies which have completely revolutionized biology in final 1 decade are the invention of genome enhancing instruments and rising the stem cells/major tissue explants in outlined 3D tradition. On this regard the invention of CRISPR-Cas9 as a selected gene enhancing software and organoid tradition from grownup stem cell has offered simple useful instruments to uncover the method of organ growth and likewise modeling most cancers.
Genetically modified organoids have been developed by sequential knockout and knockin of driver mutations by genome enhancing adopted by niche-based choice. The modified organoids when xenotransplanted in animal fashions faithfully recapitulate the neoplastic occasions of human tumors. The current assessment focuses on the merging of those two highly effective applied sciences in understanding the complexities of colon and liver most cancers.
Functions and challenges of CRISPR-Cas gene-editing to illness therapy in clinics
Clustered recurrently interspaced brief palindromic repeats (CRISPR)-associated programs (Cas) are environment friendly instruments for concentrating on particular genes for laboratory analysis, agricultural engineering, biotechnology, and human illness therapy.
Cas9, by far essentially the most extensively used gene-editing nuclease, has proven nice promise for the therapy of hereditary illnesses, viral an infection, cancers, and so forth. Current stories have revealed that another forms of CRISPR-Cas programs may additionally have stunning potential to affix the fray as gene-editing instruments for numerous purposes.
Regardless of the speedy progress in fundamental analysis and medical assessments, some underlying issues current steady, vital challenges, equivalent to enhancing effectivity, relative problem in supply, off-target results, immunogenicity, and so on.
This text summarizes the purposes of CRISPR-Cas from bench to bedside and highlights the present obstacles which will restrict the utilization of CRISPR-Cas programs as gene-editing toolkits in precision medication and provide some viewpoints which will assist to deal with these challenges and facilitate technical growth. CRISPR-Cas programs, as a strong gene-editing strategy, will provide nice hopes in medical therapies for a lot of people with at the moment incurable illnesses.
Duchenne muscular dystrophy cell tradition fashions created by CRISPR/Cas9 gene enhancing and their software in drug screening
Gene enhancing strategies are a horny therapeutic possibility for Duchenne muscular dystrophy, they usually have a direct software within the technology of analysis fashions. To generate myoblast cultures that may very well be helpful in in vitro drug screening, we now have optimised a CRISPR/Cas9 gene version protocol.
We’ve efficiently used it in wild sort immortalised myoblasts to delete exon 52 of the dystrophin gene, modelling a standard Duchenne muscular dystrophy mutation; and in affected person’s immortalised cultures we now have deleted an inhibitory microRNA goal area of the utrophin UTR, resulting in utrophin upregulation.
We’ve characterised these cultures by demonstrating, respectively, inhibition of dystrophin expression and overexpression of utrophin, and evaluating the expression of myogenic elements (Myf5 and MyH3) and parts of the dystrophin related glycoprotein complicated (α-sarcoglycan and β-dystroglycan).
To reveal their use within the evaluation of DMD therapies, we now have carried out exon skipping on the DMDΔ52-Mannequin and have used the unedited DMD cultures/ DMD-UTRN-Mannequin combo to evaluate utrophin overexpression after drug therapy.
Whereas the sensible use of DMDΔ52-Mannequin is restricted to the validation to our gene enhancing protocol, DMD-UTRN-Mannequin presents a attainable therapeutic gene version goal in addition to a helpful optimistic management within the screening of utrophin overexpression medication.
Utility of the amplification-free SERS-based CRISPR/Cas12a platform within the identification of SARS-CoV-2 from medical samples
The management of contagious or refractory illnesses requires early, speedy diagnostic assays which are easy, quick, and easy-to-use. Right here, easy-to-implement CRISPR/Cas12a-based diagnostic platform by Raman transducer generated by Raman enhancement impact, time period as SERS-CRISPR (S-CRISPR), are described.
The S-CRISPR makes use of high-activity noble metallic nanoscopic supplies to extend the sensitivity within the detection of nucleic acids, with out amplification. This amplification-free platform, which will be carried out inside 30-40 min of incubation time, is then used for detection of SARS-CoV-2 derived nucleic acids in RNA extracts obtained from nasopharyngeal swab specimens (n = 112).
Reliance Sharps Disposal 1 Application Kit |
|||
| SAF1426 | Scientific Laboratory Supplies | EACH | EUR 15.72 |
Reliance Bio-Hazard Kit 5 Application in Aura Box |
|||
| SAF1424 | Scientific Laboratory Supplies | EACH | EUR 17.33 |
Reliance Sharps Disposal 5 Application Kit in Aura Box |
|||
| SAF1428 | Scientific Laboratory Supplies | EACH | EUR 110.58 |
Reliance Sharps Kit 2 Application in Large Compact Aura |
|||
| SAF1430 | Scientific Laboratory Supplies | EACH | EUR 44.69 |
COMPRESSION SEALER EASY PRESS, MANUAL, FOR APPLICATION OF AXYMATS TO MICROPLATES |
|||
| IT-EP-R | CORNING | 1/pk | EUR 1270.8 |
|
Description: Sealing Products; Sealing mats - Axygen |
|||
CRISPR-Cas9 Antibody |
|||
| 48200-100ul | SAB | 100ul | EUR 399.6 |
CRISPR-Cas9 Antibody |
|||
| 48200-50ul | SAB | 50ul | EUR 286.8 |
CRISPR / hCas9 Adenovirus |
|||
| AVP010 | GenTarget | 1x109 IFU/ml x 200ul | EUR 541.2 |
|
Description: pre-made adenovirus expresses the neclear penetrated, human codon optimized wild-type Cas9 endonuclease, provided in DMEM medium. |
|||
CRISPR-Cas9 Antibody |
|||
| RQ4684 | NSJ Bioreagents | 100ul | EUR 419 |
CRISPR-Cas9 SP Antibody |
|||
| 49498-100ul | SAB | 100ul | EUR 399.6 |
CRISPR-Cas9 SP Antibody |
|||
| 49498-50ul | SAB | 50ul | EUR 286.8 |
Scrambled sgRNA CRISPR Lentivector |
|||
| K018 | ABM | 1.0 ug | EUR 184.8 |
Anti-CRISPR Cas9 antibody |
|||
| STJ120286 | St John's Laboratory | 100 µl | EUR 631.2 |
CRISPR sgRNA Synthesis Kit |
|||
| K1251-25 | Biovision | each | EUR 483.6 |
CRISPR-Cas9 SP Conjugated Antibody |
|||
| C49498 | SAB | 100ul | EUR 476.4 |
TDOR sgRNA CRISPR Lentivector set () |
|||
| K9000801 | ABM | 3 x 1.0 ug | EUR 406.8 |
Classic CRISPR sgRNA Synthesis Kit |
|||
| K1252-25 | Biovision | 25 Reactions | EUR 526.8 |
|
Description: Classic CRISPR sgRNA Synthesis Kit |
|||
CRISPR Genomic Cleavage Detection Kit |
|||
| G932 | ABM | 25 Reactions | EUR 246 |
CRISPR Cas9 Monoclonal Antibody [7A9] |
|||
| A-9000-010 | EpiGentek | 10 ug | EUR 71.5 |
CRISPR Cas9 Monoclonal Antibody [7A9] |
|||
| A-9000-050 | EpiGentek | 50 ug | EUR 200.2 |
CRISPR Cas9 Monoclonal Antibody [7A9] |
|||
| A-9000-100 | EpiGentek | 100 ug | EUR 355.3 |
CRISPR Cas9 Monoclonal Antibody [7A9] |
|||
| A-9000 | EpiGentek |
|
|
CRISPR Genomic Cleavage Detection Kit |
|||
| K1250-25 | Biovision | each | EUR 483.6 |
Express CRISPR sgRNA Synthesis Kit |
|||
| K1253-25 | Biovision | each | EUR 639.6 |
LAG3 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78053 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: Lymphocyte-activation gene 3 (LAG3, CD223) is a cell surface protein that belongs to the immunoglobulin (Ig) superfamily. LAG3 is expressed on activated T-cells, Natural Killer cells, B-cells, and plasmacytoid dendritic cells. Its main ligand is the MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T-cells in a similar fashion as CTLA-4 and PD-1, and has been reported to play a role in T-reg suppressive function. A number of LAG3 antibodies are in preclinical development for the treatment of cancer and autoimmune disorders. LAG3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1, because antibodies targeting CTLA-4 or PD-1 only activate effector T-cells while failing to inhibit T-reg activity, whereas an antagonist LAG3 antibody can both activate effector T-cells (by downregulating the LAG3 inhibiting signal) and inhibit induced (i.e. antigen-specific) T-reg suppressive activity. The LAG3 CRISPR Lentiviruses are replication incompetent, HIV-based, VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human LAG3 (GenBank Accession #NM_002286) driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ _x000D_ |
|||
CTLA4 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78054 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: CTLA4 (Cytotoxic T-Lymphocyte Associated Protein), also known as CD152, is a protein receptor that functions as an immune checkpoint. It is expressed by activated T-cells and transmits an inhibitory signal to T-cells. CTLA4 is homologous to the T-cell co-stimulatory protein CD28, and both molecules bind to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells. CTLA4 binds CD80 and CD86 with greater affinity and avidity than CD28, thus enabling it to out-compete CD28 for its ligands and act as an "off" switch when bound to CD80 or CD86. CTLA4 is an important immunotherapy target for the treatment of cancer and autoimmune diseases._x000D_ The CTLA4 CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human CTLA4, GenBank Accession #NM_005214, driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ |
|||
TCR CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78055 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: The T-Cell Receptor (TCR) is found on the surface of T-cells and is responsible for recognizing antigens bound to MHC (Major Histocompatibility Complex) molecules. Activation of the TCR results in activation of downstream NFAT signaling. The TCR consists of a heterodimer of two different protein chains, of which the alpha (α) and beta (β) chains are the predominant chains._x000D_ The TCR CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human TRAC (T-Cell Receptor Alpha Constant) and human TRBC1 (T-Cell Receptor Beta Constant 1) regions of the α and β chains._x000D_ The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ |
|||
CD47 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78056 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: CD47 (also known as Rh-associated protein, GP42, Integrin-Associated Protein (IAP), or Neurophilin) is an immunoglobulin-like protein that interacts with its receptor, Signal-regulatory protein alpha (SIRPα), on macrophages. This binding interaction regulates transmigration, oxidative burst cytokine production, and phagocytosis, generating a "don't eat me" signal. CD47 is ubiquitously expressed on the surface of normal cells, but is overexpressed in numerous cancer cells where it is thought to contribute to the resistance of tumors to phagocyte-dependent clearance._x000D_The CD47 CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human CD47 (NM_198793.2) driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ |
|||
TIGIT CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78058 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: TIGIT (T-cell immunoreceptor with Ig and ITIM domains; VSTM3; VSIG9) is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells and activated CD4+, CD8+, and regulatory T-cells. Interaction with the Poliovirus Receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits either the Src homology (SH) domain-containing tyrosine phosphatases SHP1 and SHP2, or the Inositol phosphatase SHIP1 and SHIP2, to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-κB and NFAT T-cell receptor (TCR) signaling, which blocks T-cell proliferation and cytokine production. TIGIT also serves as a competitive inhibitor of CD226, a costimulatory receptor for CD155. TIGIT-targeting antibodies which block this T-cell intrinsic inhibitory effect have shown enhanced anti-tumor and anti-viral functions in preclinical studies._x000D_ The TIGIT CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human TIGIT (GenBank Accession #NM_173799) driven by a U6 promoter._x000D_ The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest. |
|||
CRBN CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78517 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: Cereblon (CRBN) forms an E3 ubiquitin ligase complex which is responsible for ubiquitinating proteins that regulate various developmental processes. CRBN also binds to Calcium Activated Potassium Channel subunit alpha-1 (KCNMA1) to regulate ion transport. Moreover, mutations in CRBN may play an underlying role in tumor cells acquiring resistance to immunotherapy.The CRBN CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human CRBN.The DNA transduced by this lentivirus integrates randomly into the cellular genome to express both Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type. |
|||
TGFBR2 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78535 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: Transforming growth factor receptor beta 2 (TGFBR2) encodes the TGF-β receptor protein, which is a transmembrane protein that forms a heterodimeric complex with other receptor proteins and binds TGF-β. This receptor/ligand complex phosphorylates proteins which regulate cell proliferation, cell cycle arrest, wound healing, and immunosuppression. Mutations in TGFBR2 have been linked with Marfan syndrome and the development of various types of tumors.The TGFBR2 CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles ready to infect most types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human TGFBR2.The DNA transduced by this lentivirus integrates randomly into the cellular genome to express both Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Knockdown efficiency is dependent on cell type. |
|||
FCGR2A CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78537 | BPS Bioscience | 500 µl x 2 | EUR 795 |
|
Description: Fc Gamma Receptor 2A (also known as CD32A, Fc-gamma-RIIa, FcgRIIa) is a low affinity Fc receptor for immunoglobulin G, encoded by the FCGR2A gene. Fc Gamma Receptor 2A is a cell surface receptor that is expressed on a variety of immune cells such as macrophages and neutrophils. It is involved in phagocytosis and in the clearing of spent immune complexes from the circulation. A polymorphism in FCGR2A has been associated with increased risks of nephritis and lupus.The FCGR2A CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to transduce into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human FCGR2A. |
|||
NLRP3 CRISPR/Cas9 Lentivirus (Integrating) |
|||
| 78545 | BPS Bioscience | 500 µl x 2 | EUR 995 |
|
Description: NLR family Pyrin domain containing 3 (NLRP3) is expressed in macrophages and is a component of inflammasomes. NLRP3 detects uric acid and extracellular ATP in damaged tissue and interacts with a pro-apoptotic protein that recruits caspases. This complex is also an upstream activator of NF-κB signaling and triggers an immune response as part of the innate immune system. Mutations in NLRP3 are known to cause autoinflammatory and neuroinflammatory diseases, such as Alzheimer's, Parkinson's, and prion disease. The NLRP3 CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles ready to infect most types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human NLRP3 (Figure 1 and Table 1), allowing the knockdown of NLRP3 in transduced cells.The DNA transduced by the integrating lentivirus integrates randomly into the cellular genome to express both Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Knockdown efficiencies also depend on the cell type. |
|||
CRISPR-Cas9 SP recombinant monoclonal antibody |
|||
| A5899 | Bimake | 100ul X 3 | EUR 714 |
|
Description: A recombinant monoclonal antibody from rabbit against human CRISPR-Cas9 SP for WB,ELISA |
|||
CRISPR / hCas9 Adenovirus, in vivo ready |
|||
| AVP010-PBS | GenTarget | 1x1011 IFU/ml x 50ul | EUR 852 |
|
Description: pre-made adenovirus expresses the neclear penetrated, human codon optimized wild-type Cas9 endonuclease, provided in PBS solution. |
|||
Anti-CRISPR-Cas9 Rabbit Monoclonal Antibody |
|||
| M30929-1 | BosterBio | 100ug/vial | EUR 476.4 |
|
Description: Rabbit Monoclonal CRISPR-Cas9 Antibody. Validated in IP, IF, WB and tested in Streptococcus pyogenes. |
|||
Mrpl34 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7195101 | ABM | 3 x 1.0 ug | EUR 406.8 |
Olr45 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7195201 | ABM | 3 x 1.0 ug | EUR 406.8 |
Olr1086 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7195301 | ABM | 3 x 1.0 ug | EUR 406.8 |
Olr1380 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7195401 | ABM | 3 x 1.0 ug | EUR 406.8 |
Olr1020 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7195501 | ABM | 3 x 1.0 ug | EUR 406.8 |
Ttc5 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7195601 | ABM | 3 x 1.0 ug | EUR 406.8 |
Cd302 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7195701 | ABM | 3 x 1.0 ug | EUR 406.8 |
Actl6a sgRNA CRISPR Lentivector set (Rat) |
|||
| K7195801 | ABM | 3 x 1.0 ug | EUR 406.8 |
Ap4m1 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7195901 | ABM | 3 x 1.0 ug | EUR 406.8 |
Gpr64 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7196001 | ABM | 3 x 1.0 ug | EUR 406.8 |
In contrast with the quantitative reverse transcription polymerase chain response (RT-qPCR), the sensitivity and specificity of S-CRISPR reaches 87.50% and 100%, respectively. Normally, the S-CRISPR can quickly determine the RNA of SARS-CoV-2 RNA with out amplification and is a possible technique for nucleic acid level of care check (POCT).
